| Patient | Vivekananda |
|---|---|
| Date of birth | 1991-01-12 |
| Identifiers | MRN HR-NI032-SYN; SSN (made up) 000-32-9014 |
| Document date | 2026-10-27 |
| Author | Anjali Thornbury-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review after seven months away, a week after an asthma attack. [S]
Swami Vivekananda returns a week after the sick visit for a moderate asthma attack, and nine days after coming home from seven months of travel in the mountains. He finished five days of prednisone three days ago; his glucose rose to 210 to 268 mg/dL before the evening meal during the course and came back to 120 to 140 fasting within two days, without other treatment. The nurse telephoned on the second day. He has used the budesonide-formoterol inhaler two to four times a day; he has woken twice in the week with tightness, and the attacks are milder. While away he took metformin 2000 mg, losartan and atorvastatin, messaged his fasting readings (110 to 135 mg/dL), and kept his fortnightly fasts with fruit and milk. He could not find a laboratory for the three-month blood tests, so they were not done. He completed four of six video sessions for insomnia and falls asleep within about 45 minutes on most nights. The festival of the goddess is in two weeks and he intends to keep its fast. [S]
| Element | Detail |
|---|---|
| Asthma | Reliever two to four times a day; woken twice in a week; Asthma Control Test 15 |
| Prednisone and glucose | Evening glucose 210 to 268 mg/dL during the course; settled within two days |
| While away | Fasting glucose 110 to 135 mg/dL; three-month laboratory tests not done |
| Sleep | Four video sessions of cognitive behavioral therapy for insomnia; about 45 minutes to fall asleep |
| Coming fast | A festival fast in two weeks |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Wheeze and tightness on two nights this week; cough in the mornings |
| Constitutional | Negative | Energy returning; weight 74.8 kg |
| Cardiovascular | Negative | No chest pain or ankle swelling |
| Genitourinary | Negative | No nocturia; no urinary symptoms |
| Psychiatric | Negative | Cheerful; PHQ-2 1 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week | 1000 mg with the evening meal | Oral route | 2026-02-16 to 2026-03-23 | completed | S |
| Metformin extended-release 500 mg tablets: four tablets (2000 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink | 2000 mg with the evening meal | Oral route | 2026-03-23 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Atorvastatin 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) each morning for five days | 40 mg each morning for five days | Oral route | 2026-10-20 to 2026-10-24 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer, one inhalation as needed for wheeze or breathlessness, no more than 12 inhalations a day, until lung function testing | One inhalation as needed | Respiratory tract route | 2026-10-20 to 2026-10-27 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; skip it on any day of fasting without water, and stop it when unable to eat or drink | One tablet daily | Oral route | 2026-10-27 | active | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one as needed, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-10-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 172 | cm | S |
| 2026-10-27 | Body weight | 74.8 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 82 | /min | S |
| 2026-10-27 | Respiratory rate | 16 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.9 | % | Below 5.7% is normal; 6.5% or more diabetes; his target below 7% | High | S |
| 2026-10-27 | Glucose [Mass/volume] in Serum or Plasma | 124 | mg/dL | Fasting; 126 mg/dL or more indicates diabetes | High | S |
| 2026-10-27 | Albumin/Creatinine [Mass Ratio] in Urine | 34 | mg/g | 30 to 299 moderately increased; 300 or more severely increased | High | S |
| 2026-10-27 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 103 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-27 | Cholesterol [Mass/volume] in Serum or Plasma | 152 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 39 | mg/dL | 40 mg/dL or more for men | Low | S |
| 2026-10-27 | Triglyceride [Mass/volume] in Serum or Plasma | 146 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 84 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-10-27 | FEV1 --pre bronchodilation | 2.95 | L | Lower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations) | Low | S |
| 2026-10-27 | FEV1 --post bronchodilation | 3.42 | L | Lower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations) | Normal | S |
| 2026-10-27 | FEV1 measured/predicted | 77 | % | GLI Global race-neutral equations | Low | S |
| 2026-10-27 | FEV1/FVC | 0.66 | {ratio} | Lower limit of normal for his age (GLI Global) | Low | S |
| 2026-10-27 | FEV1/FVC --post bronchodilation | 0.75 | {ratio} | Lower limit of normal for his age (GLI Global) | Normal | S |
| 2026-10-27 | Fractional concentration of exhaled nitric oxide | 44 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | High | S |
| 2026-10-27 | Total score [ACT] | 15 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 74.8 kg, BMI 25.3; blood pressure 126/78, pulse 82; oxygen saturation 97 percent |
| Respiratory | Faint expiratory wheeze on forced expiration |
| Cardiovascular | Regular; no edema |
| Feet | Skin intact after months of walking; no calluses or sores |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptide | resolved | confirmed | R73.9 | S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit. |
| Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetes | active | confirmed | E11.65 | S — Synthetic modern confirmation and classification linked to his documented diabetes. |
| Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six months | resolved | confirmed | R80.9 | S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed. |
| Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be taken | resolved | confirmed | R03.0 | S — Synthetic finding; not a claim about his real blood pressure. |
| Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetes | active | confirmed | I10 | S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded. |
| Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditation | active | confirmed | G47.00 | S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep. |
| Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36 | active | confirmed | E78.2 | S — Synthetic cardiovascular risk factor. |
| Attacks of wheeze and breathlessness for three weeks since coming down from the mountains to the damp plains, the worst last night with a sense of suffocation: peak flow 330 L/min (56 percent of predicted), oxygen saturation 94 percent, rising to 410 L/min after bronchodilator; no fever, edema or chest pain; chest X-ray and ECG without heart failure or pneumonia. Asthma to be confirmed with spirometry | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to his documented suffocating attacks of asthma on his return to Belur. Superseded by the diagnosis a week later. |
| Asthma, adult onset, confirmed: FEV1 2.95 L (77 percent predicted) rising 470 mL (16 percent) after bronchodilator, FEV1/FVC 0.66 rising to 0.75; FeNO 44 ppb; brought on by damp air and smoke; one moderate attack treated with prednisone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to his documented attacks of asthma. |
| Diabetic kidney disease, CKD stage G1 A2: moderately increased albuminuria on three samples over eight months (46, 41 and 34 mg/g) with eGFR above 90 | active | confirmed | E11.21 | S — Synthetic modern diagnosis linked to his documented albuminuria and Bright's disease; not a claim about the cause of his real kidney disease. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | A1c | Quarterly until at goal and after a change in therapy | Completed today | 6.9 percent, at target |
| Laboratory | A1c three months after the change in therapy | Quarterly after a change in therapy | Deferred | Missed: due three months after the metformin dose increase, while he was travelling in the mountains, and he could not find a laboratory. No harm resulted judging by today's A1c of 6.9 percent and his monthly fasting readings of 110 to 135 mg/dL. Corrective action: a point-of-care or mail-in A1c kit and a video visit are now arranged before any journey longer than two months |
| Laboratory | Urine albumin-to-creatinine ratio, eGFR and potassium | To confirm albuminuria; then every six months at G1 A2; potassium on an ARB | Completed today | 34 mg/g, the third abnormal sample (46, 41, 34): diabetic kidney disease confirmed; eGFR 103; potassium 4.5 |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting | Deferred | Missed: due six to twelve weeks after starting atorvastatin, during his travels; done today, seven months after starting: LDL 84, triglycerides 146. No harm resulted. Corrective action: as for the A1c, testing before long journeys is now planned |
| Examination | Blood pressure, weight and BMI | Every visit | Completed today | 126/78; weight 74.8 kg, BMI 25.3 |
| Examination | Foot examination | Yearly; inspection after long walking | Completed today | Intact; no calluses or sores |
| Medication safety | SGLT2 inhibitor safety: fasting, illness, genital infection and volume | At start and every visit | Completed today | Fasting and sick-day rules given; genital hygiene advice; blood pressure 126/78; no orthostatic symptoms |
| Medication safety | Glucose during oral corticosteroids | During any steroid course | Completed today | Evening glucose 210 to 268 mg/dL during prednisone; settled without insulin |
| Self-management | Fasting plan | Before any religious fast | Completed today | Plan for the festival fast in two weeks with empagliflozin and metformin |
| Imaging | Spirometry with bronchodilator response and FeNO | At diagnosis of asthma | Completed today | FEV1 2.95 L (77 percent) to 3.42 L (+470 mL, +16 percent); FEV1/FVC 0.66 to 0.75; FeNO 44 ppb |
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 15; woken twice this week; reliever two to four times a day |
| Self-management | Review within a week of an exacerbation | Within one to seven days after any exacerbation | Completed today | Nurse call on day two; this review on day seven |
| Examination | Inhaler technique and action plan | Every visit | Completed today | Technique correct with a spacer; written plan given |
| Survey | Depression screen | Yearly and as needed | Completed today | PHQ-2 1 |
| Self-management | Vaccinations | Yearly | Completed today | Influenza and COVID-19 for the new season; hepatitis B dose 2, delayed by his travel, completes the series |
| Self-management | Insomnia treatment | Until the course is complete | Completed today | Four of six sessions done; sleep onset about 45 minutes |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Influenza vaccine, the new season; COVID-19 mRNA vaccine, the new season's formula [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, CKD and asthma monographs (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Hassanein M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022;185:109185 (PMID 35016991) (2021); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023)
Follow-up: Asthma review in four to six weeks. Diabetes and kidney review with A1c, potassium, creatinine and urine albumin in three months. Call during the festival fast if glucose is below 70 or above 300 mg/dL. Next preventive visit in the spring. [S]